AbbVie Q1 Earnings, Stock Rises on Beat and Raised 2026 Guidance

AbbVie reported Q1 adjusted EPS of $2.65, beating FactSet estimates of $2.59. The company raised its 2026 guidance. Skyrizi sales hit $4.483B.

ABBV reported first-quarter 2026 adjusted earnings per share of $2.65, beating FactSet estimates of $2.59, on net revenues of $15.0 billion — up 12.4% year-over-year. The results demonstrate that AbbVie's post-Humira transition is well advanced, with the immunology portfolio more than offsetting biosimilar competition.

Skyrizi led the performance with $4.483 billion in global Q1 net revenues, up 30.9% year-over-year, cementing its role as the company's primary growth engine. AbbVie has also filed with the FDA for a Skyrizi induction approval for Crohn's disease, which would further expand the drug's addressable patient population and sustain the growth trajectory.

Management raised its full-year 2026 adjusted EPS guidance to $14.08-$14.28, up from the prior range of $13.96-$14.16, citing sustained immunology and oncology portfolio momentum. ABBV shares rose on the results, reflecting investor confidence that the company has successfully engineered a durable post-Humira revenue base with Skyrizi and Rinvoq carrying the majority of the growth burden for the foreseeable future.

Related Stocks

ABBV